The production site inspection of levetiracetam, an antiepileptic drug of xinlitai, has been completed

At the performance presentation meeting, Yang Jianfeng, Secretary of the board of directors of xinlitai, said that the drug regulatory department had come to the company this month to inspect the production site of the antiepileptic drug levetiracetam "The domestic antiepileptic drug market has a significant growth momentum, and the company believes that the product has a good market potential." According to the website of the State Food and drug administration, the on-site inspection of levetiracetam and levetiracetam tablets declared by xinlitai for production has been completed and entered into the stage of conclusion to be reviewed According to the new drug review process, xinlitai is expected to obtain production approval in the second half of this year Xinlitai is mainly engaged in the research and development and sales of cardiovascular drugs In the crisis of the main varieties losing the standard base drug market, the company's subsequent reserve varieties echelon has become a major concern of the market In addition to xinlitai, zuoxiracetam declared by Beijing New Pharmaceutical Co., Ltd and Chongqing shenghuaxi Pharmaceutical Co., Ltd will also undergo on-site inspection this month, but only the API, not the preparation